{"id":174303,"date":"2026-09-25T18:52:30","date_gmt":"2026-09-25T18:52:30","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/174303\/"},"modified":"2026-09-25T18:52:30","modified_gmt":"2026-09-25T18:52:30","slug":"novo-nordisks-1-3-billion-deal-targets-a-big-obesity-drug-problem","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/174303\/","title":{"rendered":"Novo Nordisk&#8217;s $1.3 Billion Deal Targets a Big Obesity-Drug Problem"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">This article first appeared on <a href=\"https:\/\/www.gurufocus.com\/news\/9096949\/novo-nordisks-13-billion-deal-targets-a-big-obesitydrug-problem?utm_source=yahoo_finance&amp;utm_medium=syndication&amp;utm_campaign=headlines&amp;r=caf6fe0e0db70d936033da5461e60141\" data-ylk=\"slk:GuruFocus;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;GuruFocus&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">GuruFocus<\/a>.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo Nordisk (<a href=\"https:\/\/www.gurufocus.com\/stock\/NVO\/summary?r=caf6fe0e0db70d936033da5461e60141&amp;utm_source=yahoo_finance&amp;utm_medium=syndication&amp;utm_campaign=headlines&amp;utm_content=novo_nordisk%27s_%241.3_billion_deal_targets_a_big_obesity-drug_problem&amp;utm_term=NVO\" data-ylk=\"slk:NVO;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;NVO&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">NVO<\/a>, <a href=\"https:\/\/www.gurufocus.com\/stock\/NVO\/financials?r=caf6fe0e0db70d936033da5461e60141&amp;utm_source=yahoo_finance&amp;utm_medium=syndication&amp;utm_campaign=headlines&amp;utm_content=novo_nordisk%27s_%241.3_billion_deal_targets_a_big_obesity-drug_problem&amp;utm_term=NVO\" data-ylk=\"slk:Financials;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Financials&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Financials<\/a>), has agreed to pay up to 1.165 billion ($1.3 billion) for access to drug-delivery technology that could help the <a href=\"https:\/\/seekingalpha.com\/news\/4646973-novo-signs-up-to-13b-deal-for-nanexa-drug-delivery-technology\" data-ylk=\"slk:company%20develop%20obesity%20and%20diabetes%20treatments;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;company develop obesity and diabetes treatments&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">company develop obesity and diabetes treatments<\/a> requiring fewer injections.  <\/p>\n<p>        <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/1ab4dbcc1620f46f920ca14b8ff9422703f1a0bbbaed2a7ffb52c9d1666e029a\/lightyear_networkapi\/resizefit_w960%3Bquality_80%3Bformat_webp\/https%3A%2F%2Fuserupload.gurufocus.com%2F2103389437487652864.png\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Novo Nordisk's $1.3 Billion Deal Targets a Big Obesity-Drug Problem\" height=\"540\" width=\"960\" class=\"yf-1f8hkhu loader\"\/><\/a> <a href=\"https:\/\/www.gurufocus.com\/term\/gf-value\/NVO?r=caf6fe0e0db70d936033da5461e60141&amp;utm_source=yahoo_finance&amp;utm_medium=syndication&amp;utm_campaign=headlines&amp;utm_content=novo_nordisk%27s_%241.3_billion_deal_targets_a_big_obesity-drug_problem&amp;utm_term=NVO\" data-ylk=\"slk:NVO%20GF%20Value%20chart;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;NVO GF Value chart&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">NVO GF Value chart<\/a>           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The Danish drugmaker signed a global licensing and collaboration agreement with Sweden&#8217;s Nanexa covering its PharmaShell technology for certain therapeutic peptide drugs.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The deal could cover as many as five development programs targeting obesity, type 2 diabetes and other cardiometabolic diseases.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The potentially important part for Novo is dosing frequency. The companies plan to explore different administration schedules, including monthly and quarterly injections.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo will lead global development and commercialization of products resulting from the collaboration.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Nanexa is eligible for 615 million in upfront payments and development and regulatory milestones. Total potential payments could eventually reach 1.165 billion if specified milestones are achieved.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Nanexa could also receive low single-digit royalties on future product sales.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The agreement adds another approach to Novo&#8217;s efforts to expand its cardiometabolic pipeline beyond its existing treatments. Longer-lasting formulations could become particularly important as drugmakers compete not only on weight loss and efficacy, but also on convenience for patients taking chronic therapies.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo shares closed Thursday at $38.62, up 1.2%.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The next catalyst will be which drug candidates Novo selects for the collaboration and whether the PharmaShell technology can advance longer-acting formulations into clinical development.  <\/p>\n","protected":false},"excerpt":{"rendered":"This article first appeared on GuruFocus. Novo Nordisk (NVO, Financials), has agreed to pay up to 1.165 billion&hellip;\n","protected":false},"author":2,"featured_media":174304,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[5032,13009,272],"class_list":["post-174303","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-development","tag-diabetes-treatments","tag-novo-nordisk"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117333193334770731","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/174303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=174303"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/174303\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/174304"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=174303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=174303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=174303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}